BR122023025347A2 - Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos - Google Patents

Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos Download PDF

Info

Publication number
BR122023025347A2
BR122023025347A2 BR122023025347-7A BR122023025347A BR122023025347A2 BR 122023025347 A2 BR122023025347 A2 BR 122023025347A2 BR 122023025347 A BR122023025347 A BR 122023025347A BR 122023025347 A2 BR122023025347 A2 BR 122023025347A2
Authority
BR
Brazil
Prior art keywords
crystalline form
salt
xrpd
presents
diffractometer
Prior art date
Application number
BR122023025347-7A
Other languages
English (en)
Portuguese (pt)
Inventor
Antonio J.M. Barbosa
Original Assignee
Gb006, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gb006, Inc. filed Critical Gb006, Inc.
Publication of BR122023025347A2 publication Critical patent/BR122023025347A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
BR122023025347-7A 2015-06-12 2016-06-10 Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos BR122023025347A2 (pt)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201562175066P 2015-06-12 2015-06-12
US62/175,066 2015-06-12
US201662275655P 2016-01-06 2016-01-06
US62/275,655 2016-01-06
PCT/US2016/037067 WO2016201356A1 (en) 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
BR112017026406-4A BR112017026406A2 (pt) 2015-06-12 2016-06-10 formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico

Publications (1)

Publication Number Publication Date
BR122023025347A2 true BR122023025347A2 (pt) 2024-01-16

Family

ID=57504544

Family Applications (2)

Application Number Title Priority Date Filing Date
BR122023025347-7A BR122023025347A2 (pt) 2015-06-12 2016-06-10 Sal de meglumina ou trometamina de um composto, formas cristalinas e formulações farmacêuticas dos mesmos e seus usos
BR112017026406-4A BR112017026406A2 (pt) 2015-06-12 2016-06-10 formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017026406-4A BR112017026406A2 (pt) 2015-06-12 2016-06-10 formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico

Country Status (12)

Country Link
US (4) US10723726B2 (https=)
EP (1) EP3307722B1 (https=)
JP (1) JP2018521121A (https=)
KR (1) KR102663856B1 (https=)
CN (1) CN107848991B (https=)
AU (2) AU2016275125A1 (https=)
BR (2) BR122023025347A2 (https=)
CA (2) CA3221219A1 (https=)
ES (1) ES2896674T3 (https=)
IL (1) IL256237B (https=)
SG (1) SG10201911442XA (https=)
WO (1) WO2016201356A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018521121A (ja) 2015-06-12 2018-08-02 アドハエア ファーマシューティカルズ，インコーポレイティド （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状
WO2018126072A1 (en) * 2016-12-29 2018-07-05 Adhaere Pharmaceuticals, Inc. Heterocyclic integrin agonists
WO2018178133A1 (en) * 2017-03-30 2018-10-04 Merck Patent Gmbh Solid form of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl)methanol
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
KR20210033492A (ko) 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
WO2020108154A1 (zh) 2018-11-28 2020-06-04 罗欣药业(上海)有限公司 一种雌激素受体下调剂的盐型、晶型及其制备方法
WO2020236668A1 (en) * 2019-05-17 2020-11-26 Gb006, Inc. Leukadherin-1 alone or in combination for use in the treatment of cancer
WO2021061665A1 (en) * 2019-09-23 2021-04-01 Gb006, Inc. Integrin agonist prodrugs
WO2021096988A1 (en) 2019-11-12 2021-05-20 Gb006, Inc. Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
KR20240032679A (ko) * 2022-09-02 2024-03-12 주식회사 렉스팜텍 신규 벤포티아민 콜린염
WO2024081449A1 (en) * 2022-10-14 2024-04-18 Rush University Medical Center Cd11b agonists for treatment of autoimmune disease
CN121197154A (zh) * 2025-11-13 2025-12-26 首都医科大学附属北京天坛医院 Mac-1激动剂在制备治疗和/或缓解脑出血药物中的应用

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
US20050042213A1 (en) 2003-08-14 2005-02-24 Insight Biopharmaceuticals Ltd. Methods and pharmaceutical compositions for modulating heparanase activation and uses thereof
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
ITMI20042475A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di derivati tiazolidinonici come agenti terapeutici
US8338465B2 (en) * 2006-06-08 2012-12-25 Cornell Research Foundation, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US9023876B2 (en) * 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CN103159695B (zh) * 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
CA2882853C (en) * 2012-04-20 2021-11-23 Vineet Gupta Compounds and methods for regulating integrins
JP2018521121A (ja) 2015-06-12 2018-08-02 アドハエア ファーマシューティカルズ，インコーポレイティド （ｚ）−４−（５−（（３−ベンジル−４−オキソ−２−チオキソチアゾリジン−５−イリデン）メチル）フラン−２−イル）安息香酸の固体形状

Also Published As

Publication number Publication date
EP3307722B1 (en) 2021-08-04
JP2018521121A (ja) 2018-08-02
CA2988584C (en) 2024-01-23
US20250353840A1 (en) 2025-11-20
AU2016275125A1 (en) 2018-01-25
ES2896674T3 (es) 2022-02-25
US11111239B2 (en) 2021-09-07
US20230227443A1 (en) 2023-07-20
BR112017026406A2 (pt) 2019-04-02
US20200317657A1 (en) 2020-10-08
EP3307722A1 (en) 2018-04-18
US20180354938A1 (en) 2018-12-13
KR102663856B1 (ko) 2024-05-07
IL256237B (en) 2021-12-01
CN107848991A (zh) 2018-03-27
WO2016201356A1 (en) 2016-12-15
AU2020270457A1 (en) 2020-12-10
NZ738836A (en) 2024-03-22
EP3307722A4 (en) 2018-12-05
SG10201911442XA (en) 2020-02-27
US12227497B2 (en) 2025-02-18
US10723726B2 (en) 2020-07-28
IL256237A (en) 2018-02-28
CN107848991B (zh) 2022-01-14
KR20180016443A (ko) 2018-02-14
CA3221219A1 (en) 2016-12-15
CA2988584A1 (en) 2016-12-15
AU2020270457B2 (en) 2022-10-20

Similar Documents

Publication Publication Date Title
US12227497B2 (en) Solid forms of(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
RU2754856C2 (ru) Кристаллические формы соединения триазолопиримидина
JP6946194B2 (ja) キナーゼを調節する化合物の固体形態
US8541443B2 (en) Crystal of diamine derivative and method of producing same
CN117866042A (zh) 含有二硫化物的细胞穿透肽及其制备和使用方法
UA125025C2 (uk) Способи лікування дитячих ракових захворювань
WO2021072307A1 (en) Solid state crystalline forms of a selective potassium channel modulator
CN111093651A (zh) Ido抑制剂的无定形和结晶形式
TW201922690A (zh) 環－amp反應元素結合蛋白的抑制劑
RU2819398C2 (ru) Кристаллическая форма миметика smac, применяемого в качестве ингибитора iap, и способ ее получения
JP7587526B2 (ja) Ｉａｐ阻害剤としてのｓｍａｃ模倣物の結晶及びその製造方法
HK40063608B (zh) 一种用作iap抑制剂的smac模拟物的结晶及其制备方法
JP2015500809A (ja) 非晶質エザチオスタット非溶媒和物
HK40063608A (en) Crystallization of smac mimic used as iap inhibitor and preparation method thereof
BR122024009277A2 (pt) Formas cristalinas de um composto de triazolopirimidina
EA049146B1 (ru) Аморфные и кристаллические формы ido-ингибиторов
BR112018076443B1 (pt) Processo de preparação de formas cristalinas de um composto de triazolopirimidina
BR112019027259B1 (pt) Formas amorfas e cristalinas de inibidores da ido, seus usos, e composição farmacêutica

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.